On September 15, 2026, Ye Wang's long position ratio in GENSCRIPT BIO (01548) was passively diluted following the company's issuance of 77,126,000 new shares under a general mandate. The number of shares held by Ye Wang remained unchanged at 801.15 million shares. This was a passive change resulting from the company's new share issuance, not a direct secondary market dealing.
Prior to the dilution, Ye Wang's long position in GENSCRIPT BIO was 801.15 million shares, representing 36.36%; following the share placement, the holding remained at 801.15 million shares, with the long position ratio falling to 35.13%.
This involves related parties: Zhang Fangliang.
Source: Hong Kong Exchanges and Clearing Limited
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments